NY-AQARA
5.1.2023 15:01:57 CET | Business Wire | Press release
Aqara, a leading provider of smart home products, is set to expand its product portfolio in 2023 with the addition of innovative sensors, smart door locks, video doorbells and LED strips. Committed to providing seamless connected home experiences to millions of global users, Aqara continues to enrich its offerings with latest smart home technologies and new device types.
Video Doorbell G4 is complementary to Aqara’s indoor home cameras, and together these cameras help users to keep an eye on their homes, families and visitors anytime, anywhere. This doorbell allows highly flexible installation as it can be battery-powered or wired for continuous power. It not only supports HomeKit Secure Video and local streaming to Amazon and Google smart displays, but it will also work with Matter after the Matter specification for cameras is ready. The G4 features local, AI-enabled facial recognition, which can trigger different automations depending on the person, and the device also includes both the 7-day free cloud storage and the optional local storage via a microSD card.
Presence Sensor FP2 is a revolutionary addition to the Company’s wide-ranged sensor lineup. Based on the millimeter wave (mmWave) radar technology, the FP2 detects human presence even when the person is sitting still. It enables zone positioning, which allows users to define different zones within a room such as the bed, the dresser, or the sofa area, and the presence in each of these individual zone can trigger different automations for a more customized experience. Other features include multi-person detection, fall-detection and a built-in light sensor.
Smart Lock U100 is the first deadbolt lock from Aqara, offering a secure and convenient home access solution that can be seamlessly integrated into modern smart homes. The U100 lock is one of the few smart locks in the market that is compatible with HomeKit and supports the home key feature in Apple Wallet. Other access authentication options include fingerprints, passwords, Aqara Home app, NFC cards, and mechanical keys. Based on the Zigbee protocol, the U100 supports Matter via a compatible Aqara hub.
LED Strip T1 is a multipurpose RGB CCT lightstrip that is intended to enrich smart lighting experiences for Aqara users. It produces up to 16 million vibrant colors and tunable white light, and is addressable with gradient effects. HomeKit, Alexa and Google Home are supported, and Matter support via a compatible Aqara hub is expected to be added after its launch. The LED strip is Zigbee-based which means lower power consumption as well as less congested home Wi-Fi network, and it also serves as a repeater that enhances the Zigbee network.
These devices from Aqara will become available for purchase in the following months. For more information of these products, please check a demonstrative video here.
Committed to enabling seamless user experiences, Aqara has been working to integrate Matter into its existing and new devices. In 2023 new OTA updates will be pushed to Aqara hubs - beginning from the M2 - so that they can serve as Matter bridges and connect Aqara Zigbee devices to Matter. Moreover, the Company also confirmed a new lineup of Thread-based devices with native Matter support this year, including the Door and Window Sensor P2 and the Motion and Light Sensor P2 which are expected to hit the market in the coming months. As part of the ongoing partnerships with Aqara, both Google and Samsung are featuring these new sensors on respective booths at CES 2023, along with other Aqara devices including the Hub M2 as a Matter bridge.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005437/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom